Merck’s Blockbuster Drugs Are Losing Steam

Merck & Co. diabetes treatment Januvia sits is arranged for
Photograph by Bloomberg via Getty Images

Merck & Co (MRK) reported lower-than-expected quarterly revenue, hurt by a drop in sales of its diabetes and arthritis drugs, and a strong dollar.

The company said sales of its diabetes drug, Januvia, fell 12% to $1.45 billion in the fourth quarter, while sales of its arthritis drug, Remicade, fell 29% to $396 million.

The company forecast 2016 revenue of $38.7 billion to $40.2 billion, the top end of which was in line with the average analyst estimate.

The U.S. drugmaker’s total revenue fell 2.5% to $10.22 billion. Analysts were estimating revenue of $10.35 billion, according to Thomson Reuters I/B/E/S.

The company said a strong dollar had a 7% negative impact on its total revenue.


Net income attributable to the company fell to $976 million, or 35 cents per share, for the fourth quarter ended Dec. 31 from $7.32 billion, or $2.54 per share, from a year earlier.

Excluding special items, the company earned 93 cents per share, beating the average analyst estimate of 91 cents per share.

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.

Read More

CryptocurrencyInvestingBanksReal Estate